STATEMENT UNDER 37 CFR 3.73(b) Applicant/Patent Owner: WEX Pharmaceuticals Inc. Application No /Patent No : 6.780.436 Filed/Issue Date: August 24, 2004 Entitled: SOLID ORAL PHARMACEUTICAL FORMULATION OF MODIFIED RELEASE THAT CONTAINS AN ACID LABILE. BENZIMIDAZOLE COMPOUND WEX Pharmaceuticals Inc . a Incomprated (Name of Assignee) (Type of Assignee, e.g. corporation, partnership university, government agency, etc.) states that it is: 1 7 the assignee of the entire right, title, and interest; or an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is_______%) in the patent application/patent identified above by virtue of either: A A An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 011468 Frame 0554 , or for which a copy thereof is attached OR B A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows: 1 From: The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached The document was recorded in the United States Patent and Trademark Office at Reel ______, Frame ______, or for which a copy thereof is attached 3 From: The document was recorded in the United States Patent and Trademark Office at Reel ______, Frame _____, or for which a copy thereof is attached Additional documents in the chain of title are listed on a supplemental sheet As required by 37 CFR 3 73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3 11 INOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO See MPEP 302 081 The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee 604-616-7914 Bin Huang Printed or Typed Name CEO, WEX Pharmaceuticals Inc.

This collection of information is required by 37 CFR 373(b). The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application Confidentiality is governed by 35 U S C 122 and 37 CFR 1.11 and 1.14 This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA, 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450